The June Lab

Current Clinical Trials

---

(Last Updated 09/2011)

Translational Research subjects promising cancer therapies to early stage "proof of concept" trials. The initial trials are focused on developing ways to enhance the ability of the natural immune system to recognize and eliminate tumor cells. Trials to test this concept in the following diseases have now been approved by the Institutional Review Board at the Abramson Cancer Center at the University of Pennsylvania.

The listing that follows is a representative sample of currently open trials and is subject to change. Please check with the listed investigators for more information.

To learn more about cancer clinical trials at the University of Pennsylvania and about participating in a trial, visit Oncolink - Clinical Trials Information.
To learn more about cancer clinical trials visit www.clinicaltrials.gov

Abramson Family Cancer Research Institute Transitional Research Program: UPENN T cell trials sponsored by Carl June (Updated 9/2011)
Title	Trial ID#	PI	Cell-Biologic Product
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant of CD19+ Leukemia and Lymphoma. MORE INFO	UPCC04409	Porter	CD19 gene modified Autologous Activated T cells (CART-19)
Phase II Combination Immunotherapy after ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations with Hiltonol Plus Transfer of Vacfcine-primed Autologous T cells Followed by Lenalidomide Maintenance. MORE INFO	UPCC02710	Rapoport (UMD) Stadtmauer	MAGE A3 peptide primed activated autologous T cells with Hiltonol
Pilot Study of Donor Lymphocyte Infusions Using donor T cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed CD19+ ALL After Allogeneic Stem Cell Transplantation. MORE INFO	UPCC01410	Porter	CD19 gene modified allogeneic activated T cells (CART-19)
A Phase I, Dual-cohort, Two-site, Clinical Trial Evaluation the Safety and Activity of Redirected Autologous T cells Expressing a High Affinity TCR Specific for MAGE-A3/6 or NY-ESO-1 Administered Post ASCT in Patients with Advanced Myeloma. MORE INFO	UPCC01411	Rapoport (UMD) Stadtmauer	Gene modified MAGE/NYESO autologous T cells
Phase I clinical Trial of Autologous Mesothelin Re-directed T cells Administered Intravenously in Patients with Progressive Malignant Pleural Mesothelioma. MORE INFO	UPCC17510	Haas	Mesothelin re-directed autologous T cells
A Phase I Study of Autologous T cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 in HIV-infected Patients. MORE INFO	SB728T	Tebas	Autologous zinc finger modified T cells
A Phase I, Open Label, Single Center Study to Evaluate the Safety and Tolerability of Escalating Doses of Autologous T cells Modified with Lentiviral Vectors Expressing High Affinity Gag-Specific TCRs in HLA-A-2 Patients with HIV MORE INFO	SL9TCR	Tebas	Gene modified gag-TCR autologous T cells
Randomized Phase II Trial of CD3/CD28 Activated id-KLH Primed Autologous Lymphocytes in Subjects with Myeloma Undergoing Autologous Transplant.	UPCC07409	Stadtmauer Qazilbash (MD Anderson)	Idiotype-KLH vaccine primed activated autologous T cells